• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

对“SARS-CoV-2 抑制肺部抗凝和纤维蛋白溶解基因表达”一文的评论回复。

Response to comment on 'SARS-CoV-2 suppresses anticoagulant and fibrinolytic gene expression in the lung'.

机构信息

Versiti Blood Research Institute, Department of Cell Biology Neurobiology and Anatomy Medical College of Wisconsin, Milwaukee, United States.

Department of Pathology and Laboratory Medicine and UNC Blood Research Center, Chapel Hill, United States.

出版信息

Elife. 2022 Jan 11;11:e74951. doi: 10.7554/eLife.74951.

DOI:10.7554/eLife.74951
PMID:35014952
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8752086/
Abstract

Early in the SARS-CoV-2 pandemic, we compared transcriptome data from hospitalized COVID-19 patients and control patients without COVID-19. We found changes in procoagulant and fibrinolytic gene expression in the lungs of COVID-19 patients (Mast et al., 2021). These findings have been challenged based on issues with the samples (Fitzgerald and Jamieson, 2022). We have revisited our previous analyses in the light of this challenge and find that these new analyses support our original conclusions.

摘要

在 SARS-CoV-2 大流行早期，我们比较了住院 COVID-19 患者和没有 COVID-19 的对照患者的转录组数据。我们发现 COVID-19 患者肺部中促凝和纤维蛋白溶解基因表达的变化（Mast 等人，2021 年）。这些发现基于样本存在的问题受到了质疑（Fitzgerald 和 Jamieson，2022 年）。我们根据这一挑战重新审视了我们之前的分析，发现这些新的分析支持我们最初的结论。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4bc/8752086/7071d9aa2131/elife-74951-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4bc/8752086/16e1a76ed978/elife-74951-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4bc/8752086/7071d9aa2131/elife-74951-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4bc/8752086/16e1a76ed978/elife-74951-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4bc/8752086/7071d9aa2131/elife-74951-fig2.jpg

相似文献

1
Response to comment on 'SARS-CoV-2 suppresses anticoagulant and fibrinolytic gene expression in the lung'.对“SARS-CoV-2 抑制肺部抗凝和纤维蛋白溶解基因表达”一文的评论回复。
Elife. 2022 Jan 11;11:e74951. doi: 10.7554/eLife.74951.
2
Comment on 'SARS-CoV-2 suppresses anticoagulant and fibrinolytic gene expression in the lung'.评“SARS-CoV-2 抑制肺部抗凝和纤维蛋白溶解基因表达”一文。
Elife. 2022 Jan 11;11:e74268. doi: 10.7554/eLife.74268.
3
SARS-CoV-2 suppresses anticoagulant and fibrinolytic gene expression in the lung.SARS-CoV-2 抑制肺部的抗凝和纤维蛋白溶解基因表达。
Elife. 2021 Mar 8;10:e64330. doi: 10.7554/eLife.64330.
4
Multilevel systems biology analysis of lung transcriptomics data identifies key miRNAs and potential miRNA target genes for SARS-CoV-2 infection.肺转录组学数据的多层次系统生物学分析鉴定了 SARS-CoV-2 感染的关键 miRNAs 和潜在的 miRNA 靶基因。
Comput Biol Med. 2021 Aug;135:104570. doi: 10.1016/j.compbiomed.2021.104570. Epub 2021 Jun 12.
5
[Improving outcome of COVID-19-associated thrombosis: the need for evaluation of fibrinolytic activation].改善新型冠状病毒肺炎相关血栓形成的预后：评估纤溶激活的必要性
Rinsho Ketsueki. 2022;63(5):471-480. doi: 10.11406/rinketsu.63.471.
6
Coagulopathy and Fibrinolytic Pathophysiology in COVID-19 and SARS-CoV-2 Vaccination.新型冠状病毒病和 SARS-CoV-2 疫苗接种中的凝血障碍和纤维蛋白溶解病理生理学。
Int J Mol Sci. 2022 Mar 19;23(6):3338. doi: 10.3390/ijms23063338.
7
Thromboelastography Might Be More Applicable to Guide Anticoagulant Therapy than Fibrinolytic Therapy in Critically Ill Patients with COVID-19.在新冠重症患者中，血栓弹力图可能比纤维蛋白溶解疗法更适用于指导抗凝治疗。
J Am Coll Surg. 2021 Feb;232(2):227-229. doi: 10.1016/j.jamcollsurg.2020.11.003. Epub 2020 Nov 25.
8
SARS-CoV-2 strategically mimics proteolytic activation of human ENaC.SARS-CoV-2 策略性地模拟人类 ENaC 的蛋白水解激活。
Elife. 2020 May 26;9:e58603. doi: 10.7554/eLife.58603.
9
Thromboelastography MightBe More Applicable to Guide Anticoagulant Therapy than Fibrinolytic Therapy in Critically Ill Patients with COVID-19.在新冠肺炎危重症患者中，血栓弹力图可能比纤维蛋白溶解疗法更适用于指导抗凝治疗。
J Am Coll Surg. 2021 Jun;232(6):1021-1022. doi: 10.1016/j.jamcollsurg.2021.03.005. Epub 2021 Apr 7.
10
Identifying novel host-based diagnostic biomarker panels for COVID-19: a whole-blood/nasopharyngeal transcriptome meta-analysis.基于全血/鼻咽转录组的荟萃分析：鉴定 COVID-19 的新型宿主诊断生物标志物组合。
Mol Med. 2022 Aug 3;28(1):86. doi: 10.1186/s10020-022-00513-5.

本文引用的文献

1
Comment on 'SARS-CoV-2 suppresses anticoagulant and fibrinolytic gene expression in the lung'.评“SARS-CoV-2 抑制肺部抗凝和纤维蛋白溶解基因表达”一文。
Elife. 2022 Jan 11;11:e74268. doi: 10.7554/eLife.74268.
2
SARS-CoV-2 infection induces the activation of tissue factor-mediated coagulation via activation of acid sphingomyelinase.SARS-CoV-2 感染通过激活酸性鞘磷脂酶诱导组织因子介导的凝血激活。
Blood. 2021 Jul 29;138(4):344-349. doi: 10.1182/blood.2021010685.
3
SARS-CoV-2 suppresses anticoagulant and fibrinolytic gene expression in the lung.
SARS-CoV-2 抑制肺部的抗凝和纤维蛋白溶解基因表达。
Elife. 2021 Mar 8;10:e64330. doi: 10.7554/eLife.64330.
4
Development and validation of a 30-day mortality index based on pre-existing medical administrative data from 13,323 COVID-19 patients: The Veterans Health Administration COVID-19 (VACO) Index.基于来自 13323 例 COVID-19 患者的现有医疗行政数据开发和验证的 30 天死亡率指数：退伍军人健康管理局 COVID-19（VACO）指数。
PLoS One. 2020 Nov 11;15(11):e0241825. doi: 10.1371/journal.pone.0241825. eCollection 2020.
5
Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis.补体和组织因子富集的中性粒细胞细胞外陷阱是 COVID-19 免疫血栓形成的关键驱动因素。
J Clin Invest. 2020 Nov 2;130(11):6151-6157. doi: 10.1172/JCI141374.
6
Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19.血小板激活和血小板-单核细胞聚集体形成可触发重症 COVID-19 患者组织因子表达。
Blood. 2020 Sep 10;136(11):1330-1341. doi: 10.1182/blood.2020007252.
7
Misuse of RPKM or TPM normalization when comparing across samples and sequencing protocols.在比较不同样本和测序方案时，滥用 RPKM 或 TPM 标准化。
RNA. 2020 Aug;26(8):903-909. doi: 10.1261/rna.074922.120. Epub 2020 Apr 13.
8
Normalization of RNA-seq data using factor analysis of control genes or samples.使用对照基因或样本的因子分析对RNA测序数据进行标准化。
Nat Biotechnol. 2014 Sep;32(9):896-902. doi: 10.1038/nbt.2931. Epub 2014 Aug 24.